Effect of pharmacological treatment on cardiac biomarkers in patients with acute coronary syndrome of non–ST segment elevation with Type-2 diabetes

Autores
Joison, Agustín Néstor; Baiardi, Gustavo Carlos
Año de publicación
2016
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The acute coronary syndrome is a consequence of coronary artery disease. Creatine Kinase MB is a cardiac biochemical marker used in the diagnosis and risk stratification of patients. The diabetes is a pathology associated to acute coronary syndrome non–ST segment elevation that change the cardiac conditions, in this sense, our objective was to evaluate the modifications of cardiac biomarkers values in diabetic patients. Materials and methods: A retrospective study included 155 patients of both sexes, ages ranging from 31 to 92 years old, admitted to the coronary unit of the “Reina Fabiola†Clinic, Córdoba, Argentina was performed in the period 2014-2015. Body mass index, time consultation pain, plasmatic Creatine Kinase isoenzyme MB activity and Troponin I levels were measured. The patients were stratified into two groups: without cardiovascular risk pathologies (Control group), n = 7; and with only type II diabetes, n = 64 treated with therapeutic doses of metformin (n= 37), and glibenclamide plus glizipide (n= 27). Results: cTnI levels were lower in both pharmacological treatments at 12 hrs when the values in control reach the highest. Similarly, CK-MB activity was lower at 8 hrs in both treatments; however at 12 hrs these values were lower only with metformin but not in glibenclamide plus glizipide treatment. These results could be showing an interaction between diabetes and pharmacological treatment upon the biomarkers values. Conclusion: The use of hypoglycemic drugs and the glycometabolic state are conditions that could modify CK-MB and cTnI release/clearance balance at 8 and 12 hrs after admission to the coronary unit.
Fil: Joison, Agustín Néstor. Universidad Catolica de Córdoba. Facultad de Ciencias Químicas; Argentina
Fil: Baiardi, Gustavo Carlos. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones Biológicas y Tecnológicas. Universidad Nacional de Córdoba. Facultad de Ciencias Exactas, Físicas y Naturales. Instituto de Investigaciones Biológicas y Tecnológicas; Argentina
Materia
CORONARY SYNDROME
CREATINE KINASE MB
DIABETES
TRPONIN I
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/42664

id CONICETDig_1a982b04058298e41412abb4c095a34f
oai_identifier_str oai:ri.conicet.gov.ar:11336/42664
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Effect of pharmacological treatment on cardiac biomarkers in patients with acute coronary syndrome of non–ST segment elevation with Type-2 diabetesJoison, Agustín NéstorBaiardi, Gustavo CarlosCORONARY SYNDROMECREATINE KINASE MBDIABETESTRPONIN Ihttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3The acute coronary syndrome is a consequence of coronary artery disease. Creatine Kinase MB is a cardiac biochemical marker used in the diagnosis and risk stratification of patients. The diabetes is a pathology associated to acute coronary syndrome non–ST segment elevation that change the cardiac conditions, in this sense, our objective was to evaluate the modifications of cardiac biomarkers values in diabetic patients. Materials and methods: A retrospective study included 155 patients of both sexes, ages ranging from 31 to 92 years old, admitted to the coronary unit of the “Reina Fabiola†Clinic, Córdoba, Argentina was performed in the period 2014-2015. Body mass index, time consultation pain, plasmatic Creatine Kinase isoenzyme MB activity and Troponin I levels were measured. The patients were stratified into two groups: without cardiovascular risk pathologies (Control group), n = 7; and with only type II diabetes, n = 64 treated with therapeutic doses of metformin (n= 37), and glibenclamide plus glizipide (n= 27). Results: cTnI levels were lower in both pharmacological treatments at 12 hrs when the values in control reach the highest. Similarly, CK-MB activity was lower at 8 hrs in both treatments; however at 12 hrs these values were lower only with metformin but not in glibenclamide plus glizipide treatment. These results could be showing an interaction between diabetes and pharmacological treatment upon the biomarkers values. Conclusion: The use of hypoglycemic drugs and the glycometabolic state are conditions that could modify CK-MB and cTnI release/clearance balance at 8 and 12 hrs after admission to the coronary unit.Fil: Joison, Agustín Néstor. Universidad Catolica de Córdoba. Facultad de Ciencias Químicas; ArgentinaFil: Baiardi, Gustavo Carlos. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones Biológicas y Tecnológicas. Universidad Nacional de Córdoba. Facultad de Ciencias Exactas, Físicas y Naturales. Instituto de Investigaciones Biológicas y Tecnológicas; ArgentinaIJMHS2016-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/42664Joison, Agustín Néstor; Baiardi, Gustavo Carlos; Effect of pharmacological treatment on cardiac biomarkers in patients with acute coronary syndrome of non–ST segment elevation with Type-2 diabetes; IJMHS; International Journal of Medical and Health Sciences; 5; 1; 1-2016; 32-372277-4505CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/http://www.ijmhs.net/journals-aid-312.htmlinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:25:51Zoai:ri.conicet.gov.ar:11336/42664instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:25:51.887CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Effect of pharmacological treatment on cardiac biomarkers in patients with acute coronary syndrome of non–ST segment elevation with Type-2 diabetes
title Effect of pharmacological treatment on cardiac biomarkers in patients with acute coronary syndrome of non–ST segment elevation with Type-2 diabetes
spellingShingle Effect of pharmacological treatment on cardiac biomarkers in patients with acute coronary syndrome of non–ST segment elevation with Type-2 diabetes
Joison, Agustín Néstor
CORONARY SYNDROME
CREATINE KINASE MB
DIABETES
TRPONIN I
title_short Effect of pharmacological treatment on cardiac biomarkers in patients with acute coronary syndrome of non–ST segment elevation with Type-2 diabetes
title_full Effect of pharmacological treatment on cardiac biomarkers in patients with acute coronary syndrome of non–ST segment elevation with Type-2 diabetes
title_fullStr Effect of pharmacological treatment on cardiac biomarkers in patients with acute coronary syndrome of non–ST segment elevation with Type-2 diabetes
title_full_unstemmed Effect of pharmacological treatment on cardiac biomarkers in patients with acute coronary syndrome of non–ST segment elevation with Type-2 diabetes
title_sort Effect of pharmacological treatment on cardiac biomarkers in patients with acute coronary syndrome of non–ST segment elevation with Type-2 diabetes
dc.creator.none.fl_str_mv Joison, Agustín Néstor
Baiardi, Gustavo Carlos
author Joison, Agustín Néstor
author_facet Joison, Agustín Néstor
Baiardi, Gustavo Carlos
author_role author
author2 Baiardi, Gustavo Carlos
author2_role author
dc.subject.none.fl_str_mv CORONARY SYNDROME
CREATINE KINASE MB
DIABETES
TRPONIN I
topic CORONARY SYNDROME
CREATINE KINASE MB
DIABETES
TRPONIN I
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv The acute coronary syndrome is a consequence of coronary artery disease. Creatine Kinase MB is a cardiac biochemical marker used in the diagnosis and risk stratification of patients. The diabetes is a pathology associated to acute coronary syndrome non–ST segment elevation that change the cardiac conditions, in this sense, our objective was to evaluate the modifications of cardiac biomarkers values in diabetic patients. Materials and methods: A retrospective study included 155 patients of both sexes, ages ranging from 31 to 92 years old, admitted to the coronary unit of the “Reina Fabiola†Clinic, Córdoba, Argentina was performed in the period 2014-2015. Body mass index, time consultation pain, plasmatic Creatine Kinase isoenzyme MB activity and Troponin I levels were measured. The patients were stratified into two groups: without cardiovascular risk pathologies (Control group), n = 7; and with only type II diabetes, n = 64 treated with therapeutic doses of metformin (n= 37), and glibenclamide plus glizipide (n= 27). Results: cTnI levels were lower in both pharmacological treatments at 12 hrs when the values in control reach the highest. Similarly, CK-MB activity was lower at 8 hrs in both treatments; however at 12 hrs these values were lower only with metformin but not in glibenclamide plus glizipide treatment. These results could be showing an interaction between diabetes and pharmacological treatment upon the biomarkers values. Conclusion: The use of hypoglycemic drugs and the glycometabolic state are conditions that could modify CK-MB and cTnI release/clearance balance at 8 and 12 hrs after admission to the coronary unit.
Fil: Joison, Agustín Néstor. Universidad Catolica de Córdoba. Facultad de Ciencias Químicas; Argentina
Fil: Baiardi, Gustavo Carlos. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones Biológicas y Tecnológicas. Universidad Nacional de Córdoba. Facultad de Ciencias Exactas, Físicas y Naturales. Instituto de Investigaciones Biológicas y Tecnológicas; Argentina
description The acute coronary syndrome is a consequence of coronary artery disease. Creatine Kinase MB is a cardiac biochemical marker used in the diagnosis and risk stratification of patients. The diabetes is a pathology associated to acute coronary syndrome non–ST segment elevation that change the cardiac conditions, in this sense, our objective was to evaluate the modifications of cardiac biomarkers values in diabetic patients. Materials and methods: A retrospective study included 155 patients of both sexes, ages ranging from 31 to 92 years old, admitted to the coronary unit of the “Reina Fabiola†Clinic, Córdoba, Argentina was performed in the period 2014-2015. Body mass index, time consultation pain, plasmatic Creatine Kinase isoenzyme MB activity and Troponin I levels were measured. The patients were stratified into two groups: without cardiovascular risk pathologies (Control group), n = 7; and with only type II diabetes, n = 64 treated with therapeutic doses of metformin (n= 37), and glibenclamide plus glizipide (n= 27). Results: cTnI levels were lower in both pharmacological treatments at 12 hrs when the values in control reach the highest. Similarly, CK-MB activity was lower at 8 hrs in both treatments; however at 12 hrs these values were lower only with metformin but not in glibenclamide plus glizipide treatment. These results could be showing an interaction between diabetes and pharmacological treatment upon the biomarkers values. Conclusion: The use of hypoglycemic drugs and the glycometabolic state are conditions that could modify CK-MB and cTnI release/clearance balance at 8 and 12 hrs after admission to the coronary unit.
publishDate 2016
dc.date.none.fl_str_mv 2016-01
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/42664
Joison, Agustín Néstor; Baiardi, Gustavo Carlos; Effect of pharmacological treatment on cardiac biomarkers in patients with acute coronary syndrome of non–ST segment elevation with Type-2 diabetes; IJMHS; International Journal of Medical and Health Sciences; 5; 1; 1-2016; 32-37
2277-4505
CONICET Digital
CONICET
url http://hdl.handle.net/11336/42664
identifier_str_mv Joison, Agustín Néstor; Baiardi, Gustavo Carlos; Effect of pharmacological treatment on cardiac biomarkers in patients with acute coronary syndrome of non–ST segment elevation with Type-2 diabetes; IJMHS; International Journal of Medical and Health Sciences; 5; 1; 1-2016; 32-37
2277-4505
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://www.ijmhs.net/journals-aid-312.html
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv IJMHS
publisher.none.fl_str_mv IJMHS
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846781811558973440
score 12.982451